Eli Lilly's olomorasib combination achieves 62% response rate in first-line lung cancer trial

• Eli Lilly presented ESMO 2026 data showing durable responses with investigational olomorasib in first-line KRAS G12C-mutant non-small cell lung cancer.
• Combinations with pembrolizumab, with or without chemotherapy, showed activity across PD-L1 expression levels.
• Safety findings were consistent with previous reports, though treatment-related adverse events caused some patients to discontinue treatment.
• Initial randomized Phase 3 results from SUNRAY-01 are expected in the first half of 2027; olomorasib remains unapproved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610250330PR_NEWS_USPR_____DE79926) on October 25, 2026, and is solely responsible for the information contained therein.